<DOC>
	<DOCNO>NCT00849368</DOCNO>
	<brief_summary>Main Study Objectives : The study conduct - evaluate minimal allopurinol azathioprine dos , combination , produce therapeutic 6-TGN level - evaluate safety tolerability different allopurinol/azathioprine dose level - ass concomitant allopurinol affect TPMT activity - ass clinical efficacy concomitant allopurinol-azathioprine therapy include patient</brief_summary>
	<brief_title>Azathioprine &amp; Allopurinol Inflammatory Bowel Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>Inclusion criterion : Able willing give write informed consent trialspecific procedure perform Signed inform consent form Age 18 65 year study entry Body Mass Index 18 30 kg/m2 Confirmed diagnosis either CROHN ` disease ulcerative colitis prior study enrollment combination clinical , endoscopic histologic criterion generally accept CD UC Normal TPMT activity &gt; 30 nmol MTG/gHb x h Insufficient disease control despite adequate therapy corticosteroid and/or salicylic acid derivative , and/or two episode steroidrequiring disease activity per year , and/or recurrence disease activity steroid dose 15 mg prednisone equivalent , and/or recurrence within 6 week steroid withdrawal . Exclusion criterion : Subjects confirm suspected hypersensitivity towards study medication Contemporaneous participation study Females : pregnancy Females : breastfeeding Prior thiopurine therapy Current previous immunosuppressive therapy except corticosteroid ( e.g . methotrexate , cyclosporine , mycophenolate mofetil , tacrolimus , infliximab TNFalpha blocker therapy ) within 3 month first drug intake Subjects clinically relevant comorbidity beyond diagnosis CROHN ` disease ulcerative colitis ( base extensive medical history , physical examination , vital sign , routine laboratory screen 12lead ECG ) Haemoglobin &lt; 12 g/dl screen examination Leucocytes &lt; 3 x 10E3/µl screen examination Lymphocytes &lt; 1.5 x 10E3/µl screen examination Thrombocytes &lt; 140 x 10E3/µl screen examination Renal disease ( creatinine clearance &lt; 60 ml/min , assess MDRD formula ) , history serious renal disease Liver disease ( GGT , alkaline phosphatase , ALAT , ASAT &gt; 2 time upper limit normal reference , know suspect liver cirrhosis ) Known suspect malignancy kind Known suspect active infection , serious infection precede 3 month Active , acute chronic , history , prior hepatitis B infection confirm positive hepatitis B serology ( positive HBsAg , AntiHBc ) . Patients positive hepatitis C screen test ( positive antiHCV ) . Patients positive HIV testing ( positive HIV 1 / 2 antibody test ) Active varicella zoster infection ( chickenpox , shingle ) Known suspect symptomatic bowel stenosis stricture , patient small bowel resection Subjects know suspect capable understanding evaluate information give part formal information policy ( informed consent ) , particular regard risk discomfort expose Subjects know suspect comply study directives / know suspect reliable trustworthy Subjects willing comply instruction duty concern subject insurance Women childbearing age potential willing capable use acceptable method contraception ( oral contraceptive , condom , diaphragm , intrauterine device ) entire study three month endofstudy evaluation . Male patient use acceptable barrier method contraception ( condom ) entire course study three month endofstudy evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>